title: The affinity of D2-like dopamine receptor antagonists determines the time to maximal effect on cocaine self-administration.
abstract: Differences in the time to maximal effect (T(max)) of a series of dopamine receptor antagonists on the self-administration of cocaine are not consistent with their lipophilicity (octanol-water partition coefficients at pH 7.4) and expected rapid entry into the brain after intravenous injection. It was hypothesized that the T(max) reflects the time required for maximal occupancy of receptors, which would occur as equilibrium was approached. If so, the T(max) should be related to the affinity for the relevant receptor population. This hypothesis was tested using a series of nine antagonists having a 2500-fold range of K(i) or K(d) values for D(2)-like dopamine receptors. Rats self-administered cocaine at regular intervals and then were injected intravenously with a dose of antagonist, and the self-administration of cocaine was continued for 6 to 10 h. The level of cocaine at the time of every self-administration (satiety threshold) was calculated throughout the session. The satiety threshold was stable before the injection of antagonist and then increased approximately 3-fold over the baseline value at doses of antagonists selected to produce this approximately equivalent maximal magnitude of effect (maximum increase in the equiactive cocaine concentration, satiety threshold; C(max)). Despite the similar C(max), the mean T(max) varied between 5 and 157 min across this series of antagonists. Furthermore, there was a strong and significant correlation between the in vivo T(max) values for each antagonist and the affinity for D(2)-like dopamine receptors measured in vitro. It is concluded that the cocaine self-administration paradigm offers a reliable and predictive bioassay for measuring the affinity of a competitive antagonist for D(2)-like dopamine receptors.
authors: Department of Psychiatry and Behavioral Neuroscience, College of Medicine, University of Cincinnati, 2170 E. Galbraith Rd., Cincinnati, OH 45237-0506, USA. andrew.norman@uc.edu
authors: Andrew B
authors: AB
authors: Norman
authors: Michael R
authors: MR
authors: Tabet
authors: Mantana K
authors: MK
authors: Norman
authors: Brittney K
authors: BK
authors: Fey
authors: Vladimir L
authors: VL
authors: Tsibulsky
authors: Ronald W
authors: RW
authors: Millard
references: J Chem Inf Model. 2005 May-Jun;45(3):750-7
references: 15921464
references: J Chromatogr. 1985 Aug 9;342(2):452-7
references: 2865269
references: J Med Chem. 1977 Jan;20(1):53-8
references: 13215
references: Science. 1976 Apr 30;192(4238):481-3
references: 3854
references: Psychopharmacology (Berl). 1984;82(1-2):135-9
references: 6141584
references: Nature. 1976 Jun 24;261(5562):717-9
references: 945467
references: Brain Res. 1988 Jul 26;456(2):317-23
references: 3208083
references: Synapse. 1998 Feb;28(2):167-75
references: 9450517
references: Brain Res. 2006 Oct 20;1116(1):143-52
references: 16942754
references: Biochem Pharmacol. 1984 Mar 15;33(6):877-87
references: 6712712
references: Psychopharmacology (Berl). 1982;78(3):204-9
references: 6296898
references: Eur J Biochem. 1998 Jan 15;251(1-2):252-61
references: 9492291
references: Psychopharmacology (Berl). 1992;106(4):455-8
references: 1349751
references: Brain Res. 1999 Aug 21;839(1):85-93
references: 10482802
references: Synapse. 2011 May;65(5):404-11
references: 20812328
references: Clin Schizophr Relat Psychoses. 2010 Apr;4(1):56-73
references: 20643630
references: J Neurosci Methods. 2011 Jan 15;194(2):252-8
references: 20974176
references: Eur J Pharmacol. 1996 May 6;303(1-2):123-8
references: 8804920
references: Br J Pharmacol Chemother. 1947 Sep;2(3):189-206
references: 20258355
references: Psychopharmacology (Berl). 1987;92(3):278-84
references: 2957716
references: Pharmacol Rev. 1957 Jun;9(2):242-6
references: 13465304
references: Brain Res Brain Res Protoc. 2005 May;15(1):38-45
references: 15878149
references: Trends Pharmacol Sci. 2007 Dec;28(12):608-14
references: 18023486